A GLP-1/GIP/glucagon triple receptor agonist fully reversed visual and spatial memory deficits in mice after mild traumatic brain injury, with protective effects lasting 30 days.
Full memory restorationVisual and spatial memory completely normalized at 7 and 30 days after mild TBI in treated mice
What the researchers found
Triagonist (GLP-1/GIP/Gcg agonist) fully mitigated mTBI-induced visual and spatial memory deficits at 7 and 30 days post-injury via balanced activation of all three receptors.
Why it matters
Mild TBI (concussion) affects millions yearly with no approved treatment. A peptide drug originally designed for metabolic disease that also protects the brain could be rapidly repurposed.
The numbers in context
Triple agonist (GLP-1/GIP/Gcg); 7-day SC treatment; fully reversed visual/spatial memory deficits at d7 and d30; protected vs oxidative stress and glutamate toxicity
How the study worked
In vitro: SH-SY5Y neuronal cells treated with Triagonist; cAMP, oxidative stress, and glutamate toxicity assays; receptor antagonist blockade experiments. In vivo: mouse 30g weight-drop mTBI model; 7 days daily subcutaneous Triagonist; memory testing at 7 and 30 days post-injury.
Who was studied
Mice with mild TBI; human neuronal cell line
What this study cannot tell us
Mouse model with unspecified group sizes; mild TBI only (not moderate/severe); mechanism of neuroprotection not fully elucidated in vivo; clinically translatable dose claim not validated in humans.
How to read the evidence
Moderate — compelling animal results with in vitro mechanistic support, but unspecified group sizes and no human data.
When this study was published
Published in 2020; multi-receptor incretin agonists have since gained momentum with tirzepatide's success.
The bigger picture
Multi-receptor incretin agonists like tirzepatide are revolutionizing metabolic medicine. This study suggests their neuroprotective benefits may extend to traumatic brain injury — a field with zero approved drugs.
Questions still open
- Would the Triagonist work if administered days after injury instead of immediately?
- Is the neuroprotection primarily from GLP-1, GIP, or glucagon receptor activation?
- Could existing multi-agonists like tirzepatide provide similar TBI protection?
Common questions
What is a triagonist?
Could this help people with concussions?
Read the original research
Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury.
Experimental neurology, 324, 113113
Citation
Li, Yazhou; Glotfelty, Elliot J; Namdar, Inbar; Tweedie, David; Olson, Lars; Hoffer, Barry J; DiMarchi, Richard D; Pick, Chagi G; Greig, Nigel H. (2020). Neurotrophic and neuroprotective effects of a monomeric GLP-1/GIP/Gcg receptor triagonist in cellular and rodent models of mild traumatic brain injury.. Experimental neurology, 324, 113113. https://doi.org/10.1016/j.expneurol.2019.113113